{"id":"W4407230737","doi":"10.1177/17588359251316176","title":"TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Astellas Pharma; Daiichi-Sankyo; Natera; Puma Biotechnology; Syndax Pharmaceuticals; Chugai Pharmaceutical; Nihon Medi-Physics; Eisai; Jazz Pharmaceuticals; Incyte; Taiho Pharmaceutical; Spectrum Pharmaceuticals; Boston Scientific Corporation; Gilead Sciences; Exelixis; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Pembrolizumab; Internal medicine; Breast cancer; Chemotherapy; Clinical endpoint; Oncology; Adjuvant; Triple-negative breast cancer; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003205957,0.002715067,0.002935334,0.0006019558,0.0005003187,0.001216924,0.001534911,0.001894196,0.008653352],"category_scores_gemma":[0.001984859,0.0009459492,0.001808996,0.000597922,0.00175423,0.001382666,0.0005527668,0.003495924,0.001440027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001327202,"about_ca_system_score_gemma":0.0023145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001316682,"about_ca_topic_score_gemma":0.002935353,"domain_scores_codex":[0.9990232,0.0005882219,0.00003910298,0.0001236177,0.00006245291,0.0001635092],"domain_scores_gemma":[0.9985396,0.0002962081,0.0003303347,0.0001209531,0.00008303214,0.0006298178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9586334,0.02319466,0.0007720438,0.0003723535,0.000396912,0.00003002264,0.00005122241,0.000404527,0.003551559,0.0001233092,0.0008793705,0.01159071],"study_design_scores_gemma":[0.8579628,0.1393965,0.0009706487,0.00001572659,0.0002042998,0.00002913325,0.00002016457,0.0002784634,0.0004386487,0.00008240982,0.00058977,0.00001132711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805014,0.002207182,0.0008614084,0.0007501349,0.000542436,0.0106489,0.002068118,0.000168876,0.0022515],"genre_scores_gemma":[0.9620349,0.00311187,0.003912147,0.002071975,0.0007209731,0.01775485,0.003114443,0.00006685443,0.007211949],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008653352,"threshold_uncertainty_score":0.02894831,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01792386089167593,"score_gpt":0.4126227275079166,"score_spread":0.3946988666162407,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}